# The Cooperative Human Tissue Network Midwestern Division (CHTN MWD)

> **NIH NIH UM1** · OHIO STATE UNIVERSITY · 2024 · $836,942

## Abstract

PROJECT SUMMARY/ABSTRACT
This proposal organizes the resources and experience of the Cooperative Human Tissue Network Midwestern
Division (CHTN MWD) for participation as an Adult Division of the NCI CHTN. Our CHTN MWD group of
pathologists is equipped to efficiently provide remnant patient consented biospecimens for basic and early
translational cancer research as well as for biomarker research studies to support personalized medicine.
Biospecimens will also be collected under a waiver of consent for non-human subjects determined research.
The Ohio State University (OSU) Hospital and James Cancer Hospital in Columbus, OH will function as the
Coordinating/Procurement Center while University Hospitals Cleveland Medical Center, Cleveland, OH, and
University of Pittsburgh Medical Center Shadyside, Pittsburgh, PA, and associated hospitals will function as
geographically distributed Procurement/Biorepository sites. The OSU Investigator Management Service will
manage the investigator applications and approvals and investigator biospecimen request networking. The OSU
Biospecimen Management Service will handle the tissue Quality Control, biospecimen storage and shipping and
CHTN fee billing, collections, and monthly accounting. OSU Tissue Procurement Services supports custom
biospecimen collection including investigator provided novel preservation fluids or methods. Available informatics
support the collection of data related to donor consents, biospecimens, investigators and billing. Shipped
biospecimens include a redacted Pathology and QC Report for each biospecimen shipped. Pathology reports at
OSU for freshly procured tissues include clinically appropriate molecular testing. Investigators may receive, if
IRB approved, extensive clinical data available from the OSU Total Cancer Care Protocol (TCCP) Honest Broker
utilizing the Information Warehouse (IW) platform and additional laboratory testing such as
immunohistochemistry, tissue microarray construction, digital microscopy or digital morphometrics. Biospecimen
donor privacy and confidentiality are essential elements of the CHTN MWD biospecimen management proposal
so that all procured biospecimens are patient consented, unless collected under waiver of consent, and coded.
Delinking is available for special tissues that were not consented at procurement. The OSU procurement program
joined the OSU Comprehensive Cancer Center (OSUCCC) in deploying the TCCP in 2016 to provide
comprehensive donor consent. Donors who consent give full use for future research of all their past, present and
future remnant biomaterials to IRB approved researchers. Procurement/Biorepository subsites have similar
consent programs in place. Scientific or technical knowledge or discoveries acquired in the conduct of our tissue
procurement/preservation program will be reported at national and international scientific and technical meetings
to contribute to the growth of biospecimen science, to recruit new investigators who have rese...

## Key facts

- **NIH application ID:** 10883971
- **Project number:** 2UM1CA239749-06
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Anil V Parwani
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $836,942
- **Award type:** 2
- **Project period:** 2019-04-09 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10883971

## Citation

> US National Institutes of Health, RePORTER application 10883971, The Cooperative Human Tissue Network Midwestern Division (CHTN MWD) (2UM1CA239749-06). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10883971. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*